Overview

Safety and Efficacy of LCL161 in Patients With Solid Tumors

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety of increasing doses of oral LCL161 in patients with solid tumors. It is primarily designed to evaluate the side effects and find the maximum tolerated dose of LCL161.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals